MMP-9、VEGF、bFGF在非何杰金淋巴瘤的表达及临床意义

Expression and Significance of MMP-9,VEGF and bFGF in non-Hodgkin's lymphoma

目的:探讨MMP-9、VEGF、bFGF在非何杰金淋巴瘤(NHL)中的表达及意义。方法:免疫组化法。结果MMP-9、VEGF、bFGF在NHL中表达率分别为43.66%、33.80%、25.35%,均高于正常淋巴结组织中的表达,差异均有显著性(Pm=0.0023,Pv=0.001,Pb=0.0049)。组5年生存率明显低于MMP-9(-)组(P=0.008)。VEGF在T细胞型中表达率高于B细胞型(P=0.019),VEGF阳性组治疗缓解率低(P=0.045)。巨块型NHL中bFGF表达率较高(P=0.028),bFGF(+)组5年生存率明显低于bFGF(-)组(P=0.041)。MMP-9、VEGF、bFGF之间无协同表达。结论:MMP-9、VEGF、bFGF在NHL中的表达高于正常淋巴组织,可能与淋巴组织恶变有关。MMP-9、bFGF均与生存期呈负相关,是NHL预后差的指标,联合检测更有助于判断预后。VEGF阳性组治疗效果差,提示VEGF阳性NHL患者加用VEGF靶向治疗可能会提高疗效。

Objective： To investigate the expression and clinical significance of Matrix Matalloproteinase 9, Vascular Endothelial Growth Factor and basic Fibroblast Growth Factor in non - Hodgkin＇ s lymphoma. Methods： The expression of MMP - 9, VEGF and bFGF were evaluated in 71 cases of non - Hodgkin＇ s lymphoma by means of immunohistochemistry. Results： The expression of MMP- 9,VEGF and bFGF were detected in non- Hedgkin＇ s lymphoma and the expression rates were 43.66%, 33.80%, 25.35 % respectively. The 5 - year survival rate of patients with MMP - 9 （ ＋ ） is lower（P= 0.008）. The positive rate of VEGF expression in T cell type was higher than in B cell type（P= 0. 019）. The complete and partial response rates were significantly higher in VEGF - negative group than in the VEGF - positive group（P= 0. 045）. The expression of bFGF was related with bulky tumor and overal survival. The positive rate of bFGF in non - bulky tumor was lower than in bulky tumor（P= 0.028）. Overal survival was lower in bFGF - positive group titan in bFGF- negative group（P= 0.041）. There was no rela- tionship among the expression of VEGF, bFGF and MMP- 9. Conclution： As well as in many other solid munors, we detected the expression of MMP- 9, VEGF and bFGF in non - Hodgkin＇ s lymphoma（NHL）. MMP- 9 and bFGF were related with overal survical and may be marks of unfavorable prognosis in non - Hodgkin＇ s lymphoma. VEGF could serve as a predictor of poor response to chemotherapy, so the combination of VEGF target drug and chemotherapy may benefit VEGF- positive patient.